English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Romiplostim is a thrombopoietin receptor agonist approved for the treatment of thrombocytopenia in patients with chronic idiopathic thrombocytopenic purpura (ITP) who had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Although thrombotic and embolic complications have been reported in patients receiving romiplostim, these have generally involved coronary artery or cerebral vascular events. Currently we report a patient with severe ITP treated with romiplostim who developed mesenteric venous thrombosis after a hemicolectomy to resect colon cancer.

Superior Mesenteric Vein Thrombosis Following Treatment of Refractory Immune Thrombocytopenic Purpura with Romiplostim